France Yersiniosis Diagnostics Treatment Market Size & Outlook, 2026-2034
France Yersiniosis Diagnostics Treatment Market Insights
- Reed Intelligence analysis indicates that the France Yersiniosis Diagnostics Treatment Market size, valued at USD 53.58 Million in 2025, is expected to expand to USD 114.13 Million by 2034.
- The France market is forecasted to expand at a CAGR of 8.77% spanning 2026–2034.
- PCR-Based Testing held the leading position among By Diagnostics Type segments in 2025, based on market size.
- Immunoassays is projected to post the fastest growth rate, sustaining its position as the most attractive By Diagnostics Type segment during the forecast horizon.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, France accounted for 4.66% of the global Yersiniosis Diagnostics Treatment Market size.
- By 2034, United States is expected to lead the global Yersiniosis Diagnostics Treatment Market in terms of market size.
- Within Europe, Germany is projected to dominate the regional Yersiniosis Diagnostics Treatment Market size by 2034.
- Spain is identified as the fastest-growing market in Europe, anticipated to reach USD 62.43 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 53.58 Million |
| Market Size In 2034 | USD 114.13 Million |
| Largest segment | PCR-Based Testing |
| Units | Revenue in USD Million |
| CAGR | 8.77% (2026-2034) |
| Segmnetation Covered | |
| By Diagnostics Type |
|
| By Treatment Type |
|
| By End-User |
|
| By Distribution Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
France Yersiniosis Diagnostics Treatment Market By Diagnostics Type 2026-2034 (USD Million)
| By Diagnostics Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCR-Based Testing | XX.x | XX.x | XX.x | 25.85 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Culture-Based Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Immunoassays | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Next-Generation Sequencing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Yersiniosis Diagnostics Treatment Market By Treatment Type 2026-2034 (USD Million)
| By Treatment Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antibiotic Therapy | XX.x | XX.x | XX.x | 25.91 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Combination Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Supportive Care | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Yersiniosis Diagnostics Treatment Market By End-User 2026-2034 (USD Million)
| By End-User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 24.14 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostic Laboratories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Yersiniosis Diagnostics Treatment Market By Distribution Channel 2026-2034 (USD Million)
| By Distribution Channel | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Direct Sales | XX.x | XX.x | XX.x | 29.15 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Online Distribution | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Third-Party Distributors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
